Li et al. indicated that patients with FTO and YTHDC2 deficiency have unfavorable disease-free survival and overall survival, suggesting the prognostic value of these m6A RNA methylation regulators in NSCLC [37]. The gene discussed is YTHDC2; the disease is non-small cell lung carcinoma.